Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr

被引:14
作者
Le Louedec, Felicien [1 ,2 ,3 ]
Puisset, Florent [1 ,2 ,3 ]
Thomas, Fabienne [1 ,2 ,3 ]
Chatelut, Etienne [1 ,2 ,3 ]
White-Koning, Melanie [1 ,2 ]
机构
[1] Canc Res Ctr Toulouse, Inserm UMR1037, Toulouse, France
[2] Univ Paul Sabatier Toulouse III, Fac Pharm, Toulouse, France
[3] Inst Univ Canc Toulouse Oncopole, Inst Claudius Regaud, Toulouse, France
来源
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2021年 / 10卷 / 10期
关键词
LIMITED-SAMPLING STRATEGY; MODELS; CARBOPLATIN;
D O I
10.1002/psp4.12689
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetic (PK) parameter estimation is a critical and complex step in the model-informed precision dosing (MIPD) approach. The mapbayr package was developed to perform maximum a posteriori Bayesian estimation (MAP-BE) in R from any population PK model coded in mrgsolve. The performances of mapbayr were assessed using two approaches. First, "test" models with different features were coded, for example, first-order and zero-order absorption, lag time, time-varying covariates, Michaelis-Menten elimination, combined and exponential residual error, parent drug and metabolite, and small or large inter-individual variability (IIV). A total of 4000 PK profiles (combining single/multiple dosing and rich/sparse sampling) were simulated from each test model, and MAP-BE of parameters was performed in both mapbayr and NONMEM. Second, a similar procedure was conducted with seven "real" previously published models to compare mapbayr and NONMEM on a PK outcome used in MIPD. For the test models, 98% of mapbayr estimations were identical to those given by NONMEM. Some discordances could be observed when dose-related parameters were estimated or when models with large IIV were used. The exploration of objective function values suggested that mapbayr might outdo NONMEM in specific cases. For the real models, a concordance close to 100% on PK outcomes was observed. The mapbayr package provides a reliable solution to perform MAP-BE of PK parameters in R. It also includes functions dedicated to data formatting and reporting and enables the creation of standalone Shiny web applications dedicated to MIPD, whatever the model or the clinical protocol and without additional software other than R.
引用
收藏
页码:1208 / 1220
页数:13
相关论文
共 40 条
  • [1] [Anonymous], 1992, NONMEM Users Guides
  • [2] NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis
    Bauer, Robert J.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (08): : 525 - 537
  • [3] A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage
    Chatelut, E
    Pivot, X
    Otto, J
    Chevreau, C
    Thyss, A
    Renée, N
    Milano, G
    Canal, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (02) : 264 - 269
  • [4] Comets E, 2017, J STAT SOFTW, V80, P1
  • [5] PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models
    Dumont, Cyrielle
    Lestini, Giulia
    Le Nagard, Herve
    Mentre, France
    Comets, Emmanuelle
    Thu Thuy Nguyen
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2018, 156 : 217 - 229
  • [6] Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling With mrgsolve: A Hands-On Tutorial
    Elmokadem, Ahmed
    Riggs, Matthew M.
    Baron, Kyle T.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (12): : 883 - 893
  • [7] Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy
    Faltaos, Demiana William
    Hulot, Jean Sebastian
    Urien, Saik
    Morel, Veronique
    Kaloshi, Gentian
    Fernandez, Christine
    Xuan, Khe Hoang
    Leblond, Veronique
    Lechat, Philippe
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 626 - 633
  • [8] Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages
    Fidler, Matthew
    Wilkins, Justin J.
    Hooijmaijers, Richard
    Post, Teun M.
    Schoemaker, Rik
    Trame, Mirjam N.
    Xiong, Yuan
    Wang, Wenping
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (09): : 621 - 633
  • [9] Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults
    Friberg, Lena E.
    Ravva, Patanjali
    Karlsson, Mats O.
    Liu, Ping
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) : 3032 - 3042
  • [10] Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies
    Gallais, Fanny
    Ysebaert, Loic
    Despas, Fabien
    De Barros, Sandra
    Dupre, Loic
    Quillet-Mary, Anne
    Protin, Caroline
    Thomas, Fabienne
    Oberic, Lucie
    Allal, Ben
    Chatelut, Etienne
    White-Koning, Melanie
    [J]. CLINICAL PHARMACOKINETICS, 2020, 59 (09) : 1171 - 1183